Evidence map›Paper›PMID 42700630›Full record

ArticleCancer genetics2026

Concurrent BCR::ABL1 and SET::NUP214 fusions in blast-phase chronic myeloid leukemia.

Meenakkshy Manoharan, Fnu Alnoor, Ping Yang, Catalina Amador-Ortiz, Amer Beitinjaneh, Sangeetha Venugopal, Xiaoqiong Wang, Yi Zhou, Roberto Ruiz-Cordero, Jennifer Chapman and 4 more

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer genetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Meenakkshy ManoharanDivision of Hematology, University of Miami Miller School of Medicine, Miami, FL, USA.
Fnu AlnoorDepartment of Pathology and Laboratory Medicine, University of Miami Miller School of Medicine, Miami, FL, USA.
Ping YangDepartment of Pathology and Laboratory Medicine, University of Miami Miller School of Medicine, Miami, FL, USA.
Catalina Amador-OrtizDepartment of Pathology and Laboratory Medicine, University of Miami Miller School of Medicine, Miami, FL, USA.
Amer BeitinjanehDivision of Transplantation and Cellular Therapy, University of Miami Miller School of Medicine, Miami, FL, USA.
Sangeetha VenugopalDivision of Hematology, University of Miami Miller School of Medicine, Miami, FL, USA.
Xiaoqiong WangDepartment of Pathology and Laboratory Medicine, University of Miami Miller School of Medicine, Miami, FL, USA.
Yi ZhouDepartment of Pathology and Laboratory Medicine, University of Miami Miller School of Medicine, Miami, FL, USA.
Roberto Ruiz-CorderoDepartment of Pathology and Laboratory Medicine, University of Miami Miller School of Medicine, Miami, FL, USA.
Jennifer ChapmanDepartment of Pathology and Laboratory Medicine, University of Miami Miller School of Medicine, Miami, FL, USA.
Felipe NovoaDivision of Hematology, University of Miami Miller School of Medicine, Miami, FL, USA.
Ellen MadarangDivision of Hematology, University of Miami Miller School of Medicine, Miami, FL, USA.
Justin WattsDivision of Hematology, University of Miami Miller School of Medicine, Miami, FL, USA.
Justin TaylorDivision of Hematology, University of Miami Miller School of Medicine, Miami, FL, USA; Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine, Miami, FL, USA. Electronic address: Jxt1091@miami.edu.

Funding

Tumor Biology Research ProgramP30CA240139 · NCI · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI George S. Grills · 2019 to 2026
$24.1M
Understanding mechanisms of BTK inhibitor and degrader resistance in patients with chronic lymphocytic leukemiaR01CA292653 · NCI · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI Justin Taylor · 2024 to 2026
$1.8M
The role of XPO1 in nuclear export of RNAR35GM151109 · NIGMS · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI Justin Taylor · 2023 to 2026
$1.5M
NCI NIH HHS P30 CA240139NCI NIH HHS R01 CA292653NIGMS NIH HHS R35 GM151109
6 · The paper itself

Abstract

introductionConcurrent atypical BCR::ABL1 transcripts and SET::NUP214 fusions are rare in chronic myeloid leukemia (CML) and may complicate disease classification and treatment decisions.

methodsClinical, morphologic, cytogenetic, fluorescence in situ hybridization, and next-generation sequencing findings were reviewed in a patient with de novo myeloid blast-phase CML.

resultsA 68-year-old man presented with hyperleukocytosis and was diagnosed with myeloid blast-phase CML harboring an atypical e13a3 BCR::ABL1 transcript and concurrent SET::NUP214 fusion. Single-agent dasatinib induced rapid remission, clearance of both fusion transcripts, and sustained molecular remission beyond 15 months.

conclusionConcurrent atypical BCR::ABL1 and SET::NUP214 fusions are rare in myeloid blast-phase CML. Despite this molecular complexity, durable molecular remission was achieved with single-agent dasatinib.

Indexed as

Atypical BCR::ABL1Blast phaseChronic myeloid leukemiaFusion geneSET::NUP214Tyrosine kinase inhibitor

Identifiers

PMID42700630
PMCPMC13634183

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.